CTX130
CRSP-ONC-003
Phase 1 mab terminated
Quick answer
CTX130 for Renal Cell Carcinoma is a Phase 1 program (mab) at CRISPR Therapeutics AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CRISPR Therapeutics AG
- Indication
- Renal Cell Carcinoma
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated